

Ref. No: 2267
Date: 07/01/26
Subject: Biologics Rheumatology

REQUEST

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs:

- Adalimumab [Humira]
- Adalimumab Biosimilars
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]

RESPONSE

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] - **64**
- Adalimumab [Humira] - **43**
- Adalimumab Biosimilars - **522**
- Apremilast [Otezla] - **<5**
- Baricitinib [Olumiant] - **64**
- Bimekizumab [Bimzelx] - **7**
- Certolizumab [Cimzia] - **37**
- Etanercept [Enbrel] - **35**
- Etanercept Biosimilars - **251**
- Filgotinib [Jyseleca] - **17**
- Golimumab [Simponi] - **52**
- Guselkumab [Tremfya] - **9**
- Infliximab [Remicade] - **0**
- Infliximab Biosimilars - **32**
- Ixekizumab [Taltz] - **6**
- Risankizumab [Skyrizi] - **<5**
- Rituximab [MabThera] - **0**
- Rituximab Biosimilars - **40**
- Sarilumab [Kevzara] - **<5**

- Secukinumab [Cosentyx] - **86**
- Tocilizumab [Ro Actemra] - **33**
- Tocilizumab Biosimilars - **38**
- Tofacitinib [Xeljanz] - **28**
- Upadacitinib [Rinvoq] - **41**
- Ustekinumab [Stelara] - **<5**
- Ustekinumab Biosimilar - **11**

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs:

- Adalimumab [Humira] **0**
- Adalimumab Biosimilars **<5**
- Bimekizumab [Bimzelx] **0**
- Certolizumab [Cimzia] **0**
- Etanercept [Enbrel] **0**
- Etanercept Biosimilars **<5**
- Golimumab [Simponi] **0**
- Infliximab [Remicade] **0**
- Infliximab Biosimilars **0**
- Ixekizumab [Taltz] **0**
- Secukinumab [Cosentyx] **<5**
- Tofacitinib [Xeljanz] **0**
- Upadacitinib [Rinvoq] **<5**